Literature DB >> 17031383

Mechanisms underlying lysophosphatidylcholine-induced potentiation of vascular contractions in the Otsuka Long-Evans Tokushima Fatty (OLETF) rat aorta.

T Matsumoto1, T Kobayashi, K Kamata.   

Abstract

BACKGROUND AND
PURPOSE: The effect of lysophosphatidylcholine (LPC) on aortic contractions in Otsuka Long-Evans Tokushima Fatty (OLETF) rats, a type 2 diabetic model, was studied. EXPERIMENTAL APPROACH: Using OLETF rats and control (Long Evans Tokushima Otsuka (LETO)) rats, the effects of LPC on the contractions induced by high-K(+) (10-40 mM), UK14,304 (10 approximately 100 nM; a selective alpha(2)-adrenoceptor agonist) and sodium orthovanadate (SOV; 10 microM approximately 3 mM) in endothelium-denuded aortae were compared. Aortic ERK activity and the mRNA expression for GPR4 (a putative LPC receptor) were also measured. KEY
RESULTS: OLETF rats exhibited (vs. age-matched LETO rats): (1) greater potentiation of high-K(+)-induced contraction by 10 microM LPC - a potentiation attenuated by 10 microM genistein, protein tyrosine kinase (PTK) inhibitor, (2) greater potentiation of UK14,304 (10 approximately 100 nM)-induced contractions by LPC (1 microM approximately 10 microM) - a potentiation attenuated by 10 microM genistein, 50 microM tyrphostin A23 (PTK inhibitor) or 10 microM PD98059 (MEK 1/2 inhibitor), (3) greater basal and LPC (1 microM)-induced ERK activities, (4) greater basal and 100 nM UK14,304-stimulated ERK2 activities in both the absence and presence of 10 microM LPC, (5) greater SOV (10 microM approximately 3 mM)-induced contractions, (6) greater potentiation of SOV-induced contractions by 10 microM LPC - a potentiation suppressed by 10 microM PD98059 or 10 microM genistein, (7) upregulation of GPR4 mRNA. CONCLUSIONS AND IMPLICATIONS: These results suggest that the LPC-induced potentiation of contractions in the OLETF rat aorta may be attributable to increased PTKs or ERK activity and/or to receptor upregulation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17031383      PMCID: PMC2014696          DOI: 10.1038/sj.bjp.0706937

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  44 in total

1.  Mechanisms underlying the chronic pravastatin treatment-induced improvement in the impaired endothelium-dependent aortic relaxation seen in streptozotocin-induced diabetic rats.

Authors:  T Kobayashi; T Matsumoto; K Kamata
Journal:  Br J Pharmacol       Date:  2000-09       Impact factor: 8.739

2.  Expression of G2A, a receptor for lysophosphatidylcholine, by macrophages in murine, rabbit, and human atherosclerotic plaques.

Authors:  Yoshiyuki Rikitake; Ken-ichi Hirata; Tomoya Yamashita; Kenji Iwai; Seiichi Kobayashi; Hiroshi Itoh; Masanori Ozaki; Junya Ejiri; Masashi Shiomi; Nobutaka Inoue; Seinosuke Kawashima; Mitsuhiro Yokoyama
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-12-01       Impact factor: 8.311

3.  Role of the extracellular signal-regulated kinase (Erk) signal transduction cascade in alpha(2) adrenoceptor-mediated vasoconstriction in porcine palmar lateral vein.

Authors:  R E Roberts
Journal:  Br J Pharmacol       Date:  2001-07       Impact factor: 8.739

4.  Activation of MAPK by modified low-density lipoproteins in vascular smooth muscle cells.

Authors:  V Velarde; A J Jenkins; J Christopher; T J Lyons; A A Jaffa
Journal:  J Appl Physiol (1985)       Date:  2001-09

5.  Sphingosylphosphorylcholine and lysophosphatidylcholine are ligands for the G protein-coupled receptor GPR4.

Authors:  K Zhu; L M Baudhuin; G Hong; F S Williams; K L Cristina; J H Kabarowski; O N Witte; Y Xu
Journal:  J Biol Chem       Date:  2001-09-04       Impact factor: 5.157

6.  Lysophosphatidylcholine potentiates vascular contractile responses in rat aorta via activation of tyrosine kinase.

Authors:  Hiroshi Suenaga; Katsuo Kamata
Journal:  Br J Pharmacol       Date:  2002-02       Impact factor: 8.739

7.  Spontaneous long-term hyperglycemic rat with diabetic complications. Otsuka Long-Evans Tokushima Fatty (OLETF) strain.

Authors:  K Kawano; T Hirashima; S Mori; Y Saitoh; M Kurosumi; T Natori
Journal:  Diabetes       Date:  1992-11       Impact factor: 9.461

Review 8.  Tyrosine kinase pathways and the regulation of smooth muscle contractility.

Authors:  M D Hollenberg
Journal:  Trends Pharmacol Sci       Date:  1994-04       Impact factor: 14.819

9.  Reduced Na(+)-K(+)-ATPase activity and plasma lysophosphatidylcholine concentrations in diabetic patients.

Authors:  R A Rabini; R Galassi; P Fumelli; N Dousset; M L Solera; P Valdiguie; G Curatola; G Ferretti; M Taus; L Mazzanti
Journal:  Diabetes       Date:  1994-07       Impact factor: 9.461

Review 10.  Sphingosylphosphorylcholine and lysophosphatidylcholine: G protein-coupled receptors and receptor-mediated signal transduction.

Authors:  Yan Xu
Journal:  Biochim Biophys Acta       Date:  2002-05-23
View more
  5 in total

1.  Enhanced estradiol-induced vasorelaxation in aortas from type 2 diabetic mice may reflect a compensatory role of p38 MAPK-mediated eNOS activation.

Authors:  Kumiko Taguchi; Akitaka Morishige; Takayuki Matsumoto; Katsuo Kamata; Tsuneo Kobayashi
Journal:  Pflugers Arch       Date:  2012-06-23       Impact factor: 3.657

2.  Enhancement of mesenteric artery contraction to 5-HT depends on Rho kinase and Src kinase pathways in the ob/ob mouse model of type 2 diabetes.

Authors:  Takayuki Matsumoto; Tsuneo Kobayashi; Keiko Ishida; Kumiko Taguchi; Katsuo Kamata
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

Review 3.  Metabolomics of Arterial Stiffness.

Authors:  Kaido Paapstel; Jaak Kals
Journal:  Metabolites       Date:  2022-04-20

4.  Effect of inhibition of extracellular signal-regulated kinase on relaxations to beta-adrenoceptor agonists in porcine isolated blood vessels.

Authors:  C O Uhiara; S P H Alexander; R E Roberts
Journal:  Br J Pharmacol       Date:  2009-12       Impact factor: 8.739

5.  Diabetic state, high plasma insulin and angiotensin II combine to augment endothelin-1-induced vasoconstriction via ETA receptors and ERK.

Authors:  T Kobayashi; T Nogami; K Taguchi; T Matsumoto; K Kamata
Journal:  Br J Pharmacol       Date:  2008-08-18       Impact factor: 8.739

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.